STAAR Surgical Company

NasdaqGM STAA

STAAR Surgical Company Gross Profit Margin for the Trailing 12 Months (TTM) ending September 27, 2024: 78.73%

STAAR Surgical Company Gross Profit Margin is 78.73% for the Trailing 12 Months (TTM) ending September 27, 2024, a 1.04% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.
  • STAAR Surgical Company Gross Profit Margin for the Trailing 12 Months (TTM) ending September 29, 2023 was 77.92%, a -0.42% change year over year.
  • STAAR Surgical Company Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was 78.25%, a 1.32% change year over year.
  • STAAR Surgical Company Gross Profit Margin for the Trailing 12 Months (TTM) ending October 01, 2021 was 77.23%, a 6.96% change year over year.
  • STAAR Surgical Company Gross Profit Margin for the Trailing 12 Months (TTM) ending October 02, 2020 was 72.20%, a -3.06% change year over year.
Key data
Date Gross Profit Margin Operating Income Margin EBT Margin Net Income Margin
Market news
Loading...
NasdaqGM: STAA

STAAR Surgical Company

CEO Mr. Thomas G. Frinzi
IPO Date Feb. 24, 1992
Location United States
Headquarters 25651 Atlantic Ocean Drive
Employees 1,056
Sector Consumer Discretionary
Industries
Description

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

Similar companies

HAE

Haemonetics Corporation

USD 79.96

0.69%

NVST

Envista Holdings Corp

USD 18.85

-0.74%

ATR

AptarGroup, Inc.

USD 154.61

0.47%

RGEN

Repligen Corporation

USD 156.55

-1.19%

COO

The Cooper Companies, Inc.

USD 89.11

-2.38%

WST

West Pharmaceutical Services, Inc.

USD 328.96

-3.13%

BDX

Becton, Dickinson and Company

USD 235.80

-0.17%

RMD

ResMed Inc.

USD 228.83

-0.62%

MMSI

Merit Medical Systems, Inc.

USD 99.89

4.44%

ICUI

ICU Medical, Inc.

USD 161.08

1.85%

HOLX

Hologic, Inc.

USD 70.20

-0.13%

ANGO

AngioDynamics, Inc.

USD 11.80

-5.30%

StockViz Staff

January 15, 2025

Any question? Send us an email